AVIR – atea pharmaceuticals, inc. - common stock (US:NASDAQ)
Stock Stats
News
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 [Seeking Alpha]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus [Yahoo! Finance]
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals (NASDAQ:AVIR) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... [Yahoo! Finance]
Form SCHEDULE 13G/A Atea Pharmaceuticals, Filed by: FMR LLC
Form 10-Q Atea Pharmaceuticals, For: Sep 30
Form 8-K Atea Pharmaceuticals, For: Nov 12
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.